##  [Dossier QC (eCTD/CTD) Checklist for China: Ensuring Error-Free Submissions](/index%2ephp/blog/dossier-qc-ectdctd-checklist-for-china-ensuring-error-free-submissions) 

    December 10, 2025 

  ![Dossier QC (eCTD/CTD) Checklist for China: Ensuring Error-Free Submissions ]()

2 min read 

- [Medicinal Products](/index%2ephp/blog-main-categories/medicinal-products)
- [Regulatory Affairs](/index%2ephp/blog-main-categories/regulatory-affairs)





 

In the competitive landscape of **China’s pharmaceutical market**, dossier accuracy determines how fast a product enters the market. The **National Medical Products Administration (NMPA)** and **Center for Drug Evaluation (CDE)** have become more stringent with **eCTD validation**, **data integrity**, and **Regulatory documentation standards**.

For companies pursuing **drug registration in China**, a comprehensive **Dossier Quality Control (QC) checklist** is vital. A single formatting error or data mismatch in the **CTD/eCTD submission** can delay approvals or trigger technical rejections.

This guide provides a **module-by-module eCTD QC checklist**, built for **China NMPA dossier submission** and aligned with **ICH CTD** and **CDE eCTD technical validation** requirements.

##  1. General QC — Before Submission

**Goal:** Validate completeness and compliance before initiating the **China drug registration process**.

**Checklist:**

- Confirm product classification (imported drug / domestic / biologic / TCM).
- Use the latest **NMPA eCTD template and CDE guidance**.
- Verify all documents are in **Simplified Chinese**.
- Ensure consistent applicant and **Marketing Authorization Holder (MAH)** details.
- Authenticate GMP, CPP, and/or FSC certificates.
- Maintain **PDF/A compliance, metadata accuracy**, and file naming integrity.
- Conduct a dossier validation pre-check.

## 2. Module 1 — Administrative & Product Information

**Goal:** Align administrative data with **NMPA medicinal product registration** requirements.

**Checklist:**

- Updated application form and PoA.
- Cover letter in Chinese.
- Local agent authorization validated.
- Labels and package inserts match **NMPA labeling rules**.
- Information required for inspection
- INN name verification
- Pharmacovigilance and/or RMP
- Translation accuracy cross-checked by QA.

## 3. Module 3 — Quality (CMC)

**Goal:** Ensure **CMC compliance for China drug submissions** and data reproducibility.

**Follow ICH Module 4 Checklist with special considerations as below:**

- .
- Analytical procedures and Specifications align with **Chinese Pharmacopoeia**.
- CoA and analytical method documentation complete.

## 4. Module 4 — Non-clinical Studies

**Goal:** Confirm non-clinical data meets **GLP and NMPA** requirements.

**Follow ICH Module 5 Checklist with considerations as below:**

- GLP statements and QA certification included.
- Toxicity and safety studies summarized.
- English-Chinese translation checked.

##  5. Module 5 — Clinical Studies

**Goal:** Verify clinical data quality for **CDE clinical dossier review**.

**Follow ICH Module 5 Checklist with considerations as below:**

- Chinese patient data or bridging study justification.
- Consistency with global clinical summaries.
- AE tables and datasets validated.
- GCP compliance statement verified.
- Clinical trial database

## 6. eCTD Technical Validation

**Goal:** Ensure the **CDE eCTD validation** passes without errors.

**Checklist:**

- Folder structure per **CDE eCTD specifications**.
- XML backbone validated.
- Hyperlinks active and metadata complete.
- Validation report archived.
- Virus self-check

## 7. Post-QC & Submission Readiness

**Goal:** Achieve final submission readiness for **China NMPA drug registration**.

**Checklist:**

- QA sign-off completed.
- Cross-module consistency confirmed.
- Version control implemented.
- Submission checksum validated.

### Why Dossier QC Matters

As China transitions fully to **ICH-aligned CTD and eCTD formats**, dossier quality now directly influences **Regulatory review timelines**, **credibility**, and **approval outcomes**.

A consistent, validated **QC process** helps avoid:

- Technical rejection by CDE
- Data inconsistency queries
- Faster first-cycle approval

Preparing a **CTD/eCTD dossier for NMPA submission**?  
 Let Freyr’s **Regulatory Affairs experts in China** help you ensure accuracy, compliance, and faster market entry.

[ **Talk to our China Regulatory Experts today**](https://www.freyrsolutions.com.cn/medicinal-products).